Stay updated on Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Revision: v3.4.3 updated from v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T19:35:26.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.4.2, replacing the previous v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-12T00:32:12.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Added Revision: v3.4.1 and removed Revision: v3.4.0. This update does not change core page content, study data, or user-facing features.
    Difference
    0.0%
    Check dated 2026-02-04T23:53:43.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Glossary display has been added to the page. Text updates include capitalization changes for QC-related labels, an added FEAR Act data note, and a new site revision tag (v3.4.0) replacing the old version (v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T19:59:35.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page shows a revision label update from v3.3.3 to v3.3.4, with no impact on study details or user-facing content. This is a minor technical update to the page version history. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:45:26.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    A new Locations section appears listing sites in Nevada, New Jersey, and South Carolina. The older state-specific location subsections were removed, and the footer’s HHS Vulnerability Disclosure link was deleted.
    Difference
    0.3%
    Check dated 2025-12-23T20:39:49.000Z thumbnail image

Stay in the know with updates to Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Loncastuximab Tesirine vs Idelalisib in Follicular Lymphoma Clinical Trial page.